Cefprozil, (E)-

CHEMBL5314373 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
407.4 g/mol
LogP
Phase
4

The E-geometric isomer of cefprozil is the active component of this oral second-generation cephalosporin antibiotic used for respiratory and skin infections. It has activity against both gram-positive organisms like Streptococcus and gram-negative organisms like Haemophilus influenzae. It is generally well tolerated with a safety profile similar to other oral cephalosporins.

Molekularmasse

407,4000 g/mol

TPSA

159,00 Ų

Wirkmechanismus

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C/C=C/C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1.O

InChI

InChI=1S/C18H19N3O5S.H2O/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9;/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26);1H2/b3-2+;/t12-,13-,17-;/m1./s1

Molecular Formula

C18H21N3O6S

HBD / HBA

5 / 8

Rotierbare Bindungen

5

Schwere Atome

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

The E-geometric isomer of cefprozil is the active component of this oral second-generation cephalosporin antibiotic used for respiratory and skin infections. It has activity against both gram-positive organisms like Streptococcus and gram-negative organisms like Haemophilus influenzae. It is generally well tolerated with a safety profile similar to other oral cephalosporins.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cefprozil, (E)- is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314373. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6436628. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.